Core Viewpoint - GLG Life Tech Corporation reported a significant decline in revenues and an increase in net loss for the third quarter of 2025, primarily due to competitive pricing pressures in the stevia market and a decrease in unit volumes sold [2][5][12]. Financial Summary - Revenues for Q3 2025 were $2.1 million, down 36% from $3.4 million in Q3 2024, attributed to decreased unit prices and volumes [2][25]. - For the first nine months of 2025, revenues decreased by 22% to $8.2 million from $10.5 million in the same period in 2024 [3][26]. - The company managed to reduce SG&A expenses by 23% in Q3 2025 and by 34% in the first nine months of 2025 compared to the previous year [4][32]. Profitability Metrics - The net loss attributable to the company from continuing operations for Q3 2025 was $5.2 million, an increase of $1.6 million from a net loss of $3.5 million in Q3 2024 [5][33]. - For the first nine months of 2025, the company reported a net income of $15.4 million, a significant increase from a net loss of $11.5 million in the same period in 2024 [5][34]. - The net loss per share for Q3 2025 was $0.13, compared to a net loss per share of $0.09 in Q3 2024 [6][35]. Cost Analysis - Cost of sales for Q3 2025 decreased to $1.8 million, down 34% from $2.8 million in Q3 2024, but the cost of sales as a percentage of revenue increased to 85% [27][28]. - For the first nine months of 2025, cost of sales was $7.0 million, a decrease of 19% from $8.6 million in the same period in 2024, with the cost of sales percentage remaining at 85% [28][30]. Corporate Developments - The company successfully transferred its Runhai subsidiary to a third party, which improved its balance sheet and reduced exposure to potential government actions in China [9][10]. - The company continues to focus on contract manufacturing arrangements to maintain production capabilities while mitigating risks associated with direct ownership of facilities in China [10][15]. Market Conditions - The stevia market has faced significant competitive pricing pressures, impacting the company's product pricing and sales volumes [12][16]. - Management has noted a potential decline in customer demand, which may be influenced by broader macroeconomic factors [16][19]. Regulatory Environment - The company faced regulatory challenges, including a cease-trade order due to delays in financial filings, but has since lifted the order and is preparing to resume trading on the NEX exchange [17][20][18].

Group 1 - The merger between DSM and Firmenich aims to create a leading company in nutrition, health, life-science ingredients, taste, and fragrance [1] - DSM is a Dutch company, while Firmenich is a Swiss company, indicating a cross-border collaboration in the merger [1] Group 2 - The merger is expected to enhance the combined company's capabilities in various sectors, potentially leading to increased market share and innovation [1] - The focus on nutrition and health aligns with current market trends emphasizing wellness and sustainability [1]

Group 1 - The company has successfully executed the Advance 2025 strategic plan, achieving significant transformation and operational streamlining [2] - Margin expansion was realized, increasing from 13% to 16%, alongside a strengthened balance sheet with 10 consecutive quarters of positive free cash flow [2] - The specialty food ingredient business experienced a volume/mix growth of 4%, and the previously loss-making algae omega-3 business was turned into a profitable nutrition platform [2] Group 2 - The Advance 2025 plan delivered a top line CAGR of 9% and an EBITDA growth of 8% [2] - The company divested its low-growth emulsifier business and invested in new capacity, particularly a lactic acid plant in Thailand, to drive future value [2] - The upcoming Bright 2030 strategic plan is expected to build on the achievements of Advance 2025 [3]

Corbion (OTCPK:CSNV.Y) 2025 Capital Markets Day November 20, 2025 04:00 AM ET Company ParticipantsPeter Kazius - CFONone - Video Narrator 3None - Video Narrator 2None - Video Narrator 1Olivier Rigaud - CEOConference Call ParticipantsNone - AnalystReg Watson - Equity AnalystNone - AnalystRobert Jan Vos - AnalystSebastian Bray - Senior Equity Research AnalystAnson Seto - Investment Banking AnalystOlivier RigaudGood morning, everyone, and welcome. I'm really pleased to host you today here in the heart of Corbi ...

BRIGHT 2030 Strategy & Financial Targets - The company aims for organic sales growth of 3-6% per annum from 2026-2028[6, 100, 123, 145] - The company targets an adjusted EBITDA margin of approximately 18% in 2028[6, 100, 123, 145] - The company projects a cumulative free cash flow of approximately €270 million over three years (2026-2028)[6, 100, 123, 145] - The company is targeting a double-digit percentage growth in EPS (Earnings Per Share) per annum from 2026-2028[123, 143, 145] - The company aims for a ROCE (Return on Capital Employed) of approximately 13% by 2028[123] Business Segment Performance & Growth - Food sales reached €769 million in 2024[41, 42, 126] - Nutrition sales reached €157 million in 2024[59, 60, 126] - Biomedical Polymers sales reached €55 million in 2024, with a target of €125 million by 2030[89, 94] - The company's natural food preservation market share is 25%[44] - The company projects to grow the Food business to €1 billion by 2030, representing approximately 4% CAGR[53, 54] - The company projects over €100 million additional Nutrition sales in the coming 5 years, reaching €275 million by 2030, representing approximately 10% CAGR[82] Sustainability & Operations - The company sources 98% of its raw materials from renewable sources[27, 33] - The company aims for a 42% reduction in Scope 1 & 2 emissions and a 25% reduction in Scope 3 emissions by 2030[29]

GMPs indicate the mood towards a particular issue and may change by the time bids open for subscription.The recent listings have lifted the About Sudeep Pharma IPOSudeep Pharma has set the price band at Rs 563–593 per equity share for its maiden Rs 895 crore IPO, which will open for subscription on November 21. The IPO will close on November 25. The anchor book will open a day earlier on November 20. Live EventsAt the lower band of Rs 563, the total offer size works out to Rs 854.5 crore, while the upper ...

Core Insights - No Street GP LP has disclosed a new investment in Darling Ingredients, acquiring approximately 2.25 million shares valued at $69.5 million, representing 4.6% of the fund's $1.5 billion in reportable U.S. equity holdings [1][2]. Company Overview - Darling Ingredients Inc. is a leading global provider of sustainable natural ingredients, converting animal by-products into high-value products, with a market capitalization of $5.5 billion and revenue of $5.8 billion for the trailing twelve months (TTM) [4][5]. - The company's net income for the TTM is reported at $107.8 million [4]. Recent Performance - As of the latest market close, shares of Darling Ingredients were priced at $34.75, reflecting a one-year decline of 15.4%, underperforming the S&P 500 by 30 percentage points [3]. - In the third quarter, Darling's net sales increased to $1.6 billion from $1.4 billion a year ago, with net income rising to $19.4 million from $16.9 million [7]. Strategic Focus - The company emphasizes bio-based solutions and environmental services, positioning itself as a key supplier for industries seeking sustainable raw materials [5]. - Darling Ingredients is advancing tax-credit monetizations, including a $125 million sale, with expectations of an additional $125 million to $175 million by year-end [9]. Investment Perspective - The investment firm No Street is focusing on companies that have been sharply repriced lower, with Darling Ingredients being a cash-flow-centric industrial name that may offer different upside potential compared to high-growth bets in its portfolio [6][10].

Core Points - Corbion has completed its share buyback program initiated on 1 September 2025, repurchasing a total of 577,615 ordinary shares at an average price of €17.3126, amounting to €9,999,990.02 [1] - In the final week of the program, 32,626 shares were bought back at an average price of €17.8606, totaling €582,721.36 [1] Compliance and Regulation - The share buyback program was executed in accordance with the European Market Abuse Regulation and within the authority granted by the Annual General Shareholders' Meeting on 14 May 2025, allowing for the repurchase of up to 10% of the issued share capital over a maximum period of 18 months [2] - Corbion has kept the market informed about the progress of the share buyback program through weekly press releases and updates on its website [3]

Ingredion Incorporated (NYSE:INGR) is included among the 15 Overlooked Dividend Stocks to Buy Right Now. UBS Lowers Price Target on Ingredion (INGR) After Q3 Miss and Operational Challenges On November 5, UBS analyst Joshua Spector cut the⁠ firm’s price targ‌et on Ingredion Incorporated (NYSE:INGR) fro‍m $130 to $119 wh‍il⁠e mainta‍ining a⁠ Ne‍utral rati⁠ng, as reported by The Fly. The analyst noted that the company’s⁠ third-quart‌er re​sults fell short of​ expectations due to op⁠erational cha‌l​l⁠enges ...

Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $1.8 billion, down 3% year-over-year, with gross profit dollars decreasing by 5% and gross margins slightly lower at 25.1% [16][18] - Reported and adjusted operating income were $249 million and $254 million, respectively [16] - Year-to-date cash from operations was $539 million, with capital expenditures net of disposals at $298 million [21][22] Business Line Data and Key Metrics Changes - Texture and Healthful Solutions net sales increased by 1%, driven by a 4% sales volume growth [16][17] - Food and Industrial Ingredients LATAM reported a net sales decrease of 6%, primarily due to weaker brewing demand and macroeconomic conditions [17][18] - Food and Industrial Ingredients U.S./Canada net sales declined by 7%, with a 5% decline in sales volume attributed to production challenges at the Argo plant [17][18] Market Data and Key Metrics Changes - LATAM market showed signs of weakening demand due to higher inflation and interest rates impacting consumer spending [9][10] - In the U.S., demand for sweeteners decreased in July and August but recovered in September [27][28] Company Strategy and Development Direction - The company is focused on driving profitable growth, particularly in Texture and Healthful Solutions, with an emphasis on clean-label ingredients [11][12] - Innovation remains a key pillar, with ongoing development of cost-effective ingredient solutions to help customers maintain quality while reducing costs [12][13] - Operational excellence initiatives are expected to yield significant savings, with a target of over $55 million in run-rate savings by the end of 2025 [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the diversified business portfolio despite recent challenges, anticipating operating income growth for the full year [4][5] - The outlook for 2025 includes expectations for net sales to be flat to down low single digits, with adjusted operating income expected to increase low to mid-single digits [22][23] Other Important Information - The company has authorized a new share repurchase program of up to eight million shares over the next three years, reflecting confidence in future growth [25][60] - The effective tax rate for 2025 is projected to be between 25.5% and 26.5% [23] Q&A Session Summary Question: Demand environment and stabilization signs - Management noted that inflation and high interest rates in LATAM are impacting consumer spending, with GDP growth forecasts for Mexico and Brazil being low [27][28] Question: Texture and Healthful Solutions segment outlook - The outlook change is driven by a diverse customer base and strong demand in food service and private label sectors [29][30] Question: Volume impacts from macro weakening and company-specific events - Approximately 12 million of the decline in U.S. Canada F&I was attributed to Argo plant issues, with the remainder related to market weakness [31][34] Question: Fourth-quarter contracting season and price-cost dynamics - Management anticipates that contracting will be influenced by inflationary pressures and higher input costs, with a cautious outlook for 2026 [37][38] Question: LATAM market and taxation impacts - The proposed sweetness tax in Mexico is expected to impact consumer behavior, but management believes the company is well-positioned to adapt [41][44] Question: Share repurchase strategy - The company plans to exceed $200 million in share repurchases in 2025, with a healthy cash balance supporting this strategy [60][61]